News and Trends 22 May 2017 Norwegian Biotech Goes for Combination Therapies in Melanoma BerGenBio has started a new Phase I/II trial evaluating the addition of its Axl inhibitor to standard of care treatments in advanced melanoma. In March, Norwegian BerGenBio beat a biotech record on the Norwegian stock exchange, raising a massive €43.55M. Now, the company is standing by its promises and just dosed the first patient in a […] May 22, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 22 May 2017 UPDATE: Argenx’s IPO soars to over €100M to prove itself in Phase II UPDATE (22/05/2017): Argenx has gone above and beyond to secure $115M (€103M) on the NASDAQ. Underwriters claimed all of the shares offered in over allotment, bringing the IPO to 50% more than the initial goal. Rather a lot for a company whose compound has yet to prove itself in Phase II. UPDATE (24/04/2017): Pricing terms have yet to be set, but the […] May 22, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 20 May 2017 A Concert Played by Human Neurons on a Petri Dish Guy Ben-Ary grew his own neurons on a Petri dish and made them perform in a concert last weekend at the Haus der Kulturen der Welt in Berlin. Last weekend I took my bike across Berlin to attend a truly unique event. It was, in fact, my first time going to a concert where one […] May 20, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2017 Irish Biotech developing New Antibiotics attracts €58M in Series B Round Iterum Therapeutics has raised €58M to fund Phase III and bring a new antibiotic to a market where innovation is lacking. Iterum Therapeutics is a biotech based in Dublin that develops new antibiotics with the aim of combating the superbug crisis. The company has just raised €58M ($65M) in Series B to fund Phase III […] May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2017 Shining new Light on how to control Cell Circuits Controlling genes with light is a new therapeutic avenue, and researchers from Finland are exploring how it can be used to tinker with the cell’s biochemical circuitry. Their findings could provide a better understanding of degenerative diseases and yield new cancer treatments. Researchers from the Turku Centre for Biotechnology at the University of Turku and Åbo […] May 19, 2017 - 2 minutesmins - By Denise Neves Gameiro Share WhatsApp Twitter Linkedin Email
News and Trends 19 May 2017 MorphoSys’ First Lanthipeptide Completes Phase I Successfully UPDATE (19/05/2017): MorphoSys has announced the completion of the Phase I study with MOR107, which has proved safe and showed dose-dependent pharmacokinetics. The drug, an agonist of the angiotensin II receptor type 2 (AT2-R), comes from the Dutch Lanthio Pharma and is the first lanthipeptide in MorphoSys’ pipeline. Originally published 21/02/2017 Lanthio Pharma has initiated a […] May 19, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2017 Spanish Biotech Clears €2.7M Funding Round for its New Stroke Drug AptaTargets has closed a €2.7M funding round, allowing the biotech to move into the clinic with its first drug candidate for acute ischemic stroke. AptaTargets, located in Madrid, is developing new therapeutic applications based on aptamers. The company is currently focussing on a single lead candidate for the treatment of the acute phase of ischemic […] May 18, 2017 - 2 minutesmins - By Melanie De Almeida Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2017 Heptares receives €4.5M Milestone for New Migraine Drug Candidate The UK biotech attacking notoriously evasive GPCRs has discovered a small molecule that could be used to treat migraine headaches. Heptares, owned by Sosei and based just outside London, will take home €4.5M ($5M) from Teva for discovering a drug candidate for migraine treatment. The small molecule is an calcitonin gene-related peptide (CGRP) agonist that could relieve patients […] May 18, 2017 - 1 minutemin - By Evelyn Warner Share WhatsApp Twitter Linkedin Email
News and Trends 18 May 2017 Italy is Getting its First-Ever Early Stage Biotech Fund for Tech Transfer AurorA-TT is making plans to raise €50M for what will be the first fund dedicated to investing in tech transfer within the Italian biotech ecosystem. AurorA-TT is a newborn company in Milan with the goal of promoting technology transfer in Italy. To do so, the plan is to raise a €50M fund dedicated to biotech. “There’s […] May 18, 2017 - 3 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 Danish Biotech Targeting Ion Channels Completes Private Placement The biotech company Saniona has announced the issue of new shares to Swedish and international investors, raising a total of €3.6M. Saniona, a Danish biotech listed on the Nasdaq First North Premier, just completed a private placement that raised €3.6M (SEK 35M) before issue costs. The funds are intended to provide the company with more flexibility […] May 17, 2017 - 1 minutemin - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 A Spanish Biosimilar of Amgen’s Blockbuster gets Ready for EU Approval Cinfa Biotech announced trial results for a biosimilar of Amgen’s Neulasta, a multi-billion blockbuster to treat chemotherapy-induced neutropenia. Cinfa Biotech is a Spanish company specialized in developing biosimilars. The biotech has announced positive results from the second clinical trial evaluating a biosimilar version of Neulasta (pegfilgrastim), Amgen’s second top-selling drug. It brought the big pharma €4.2Bn in […] May 17, 2017 - 2 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email
News and Trends 17 May 2017 Way to Success: What Role does Company Culture Play in Biotech? You’ve surely heard how great company culture is the key to the success of tech giants Google and Facebook. Does it also apply to biotech companies? Company culture is what drives employees to give their best every day for a cause they believe in. It’s what makes the best stay loyal to a firm over […] May 17, 2017 - 4 minutesmins - By Clara Rodríguez Fernández Share WhatsApp Twitter Linkedin Email